SEC Requires Peptide Pharma to Clarify Shareholding Relations for Hong Kong IPO

According to China's SEC on July 24, the regulator disclosed supplementary material requirements for Peptide Pharma's Hong Kong IPO filing. The SEC requires the company to clarify whether shareholders holding less than 5% of shares have any related-party relationships and whether shareholding percentages should be combined. Per Hong Kong Stock Exchange disclosures on April 24, Peptide Pharma submitted its IPO application with joint sponsors Jefferies and Huatai International. The SEC additionally requested clarification on controlling shareholder identification, capital injection pricing reasonableness, equity incentive arrangements, business qualifications, foreign investment compliance, and share pledge status.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments